Convergent Targets and Divergent Evidence: Herbal and Synthetic Pharmacotherapies for Psoriasis
Shrilekha Bodke *
Department of Pharmacy, Pravara Rural Education Society’s College of Pharmacy (For Women), Chincholi, Nashik-422102, Maharashtra, India.
Roshan Sanap
Department of Pharmacognosy, Pravara Rural Education Society’s College of Pharmacy (For Women), Chincholi, Nashik-422102, Maharashtra, India.
Rutuja Sanap
Department of Pharmacy, Pravara Rural Education Society’s College of Pharmacy (For Women), Chincholi, Nashik-422102, Maharashtra, India.
Akshada Wagh
Department of Pharmacy, Pravara Rural Education Society’s College of Pharmacy (For Women), Chincholi, Nashik-422102, Maharashtra, India.
*Author to whom correspondence should be addressed.
Abstract
Psoriasis is a chronic immune-mediated inflammatory disease in which therapeutic progress has been driven largely by synthetic small molecules and biologics acting on the interleukin-23/T helper 17 pathway, while herbal medicines remain widely used and continue to generate a large mechanistic and clinical literature. Previous reviews have usually examined the two groups separately, leaving unresolved whether herbal agents act on the same validated molecular nodes as synthetic drugs and whether their clinical evidence meets comparable standards. This critical narrative review compared herbal and synthetic pharmacotherapies for chronic plaque psoriasis across molecular mechanisms, clinical efficacy, safety and product quality. Literature published from January 2000 onwards was identified through structured searches of biomedical databases, a trial registry and a regional scholarly platform, supplemented by citation tracking, and was appraised with a qualitative rubric applied identically to both groups. The synthesis shows that the herbal–synthetic boundary is porous: dithranol, psoralens and the aryl hydrocarbon receptor agonist tapinarof derive from natural products, and indigo naturalis acts at least partly through the same receptor. Synthetic agents are supported by replicated, adequately powered randomised trials with standardised end points, whereas most herbal evidence comes from small, heterogeneous trials of unstandardised preparations. Topical indigo naturalis has the most coherent herbal evidence, although it derives largely from one research group. Evidence for oral Chinese herbal formulae, curcumin, Aloe vera and Tripterygium wilfordii is inconsistent, and the only placebo-controlled comparison with methotrexate found no benefit of a traditional formula. Mechanistic claims for botanicals rest heavily on the imiquimod mouse model, In vitro assays and network pharmacology, each with recognised translational limitations. Safety knowledge is asymmetric, because hepatotoxicity, adulteration with undeclared drugs and herb–drug interactions remain incompletely characterised for herbal products. Herbal pharmacotherapy is better regarded as a source of candidate targets and lead compounds than as an evidence-equivalent alternative to synthetic treatment. Standardised preparations, registered trials with active comparators and validated outcomes, target-engagement studies in human skin and systematic pharmacovigilance are required before broader clinical use can be justified.
Keywords: Psoriasis vulgaris, phytotherapy, indigo naturalis, aryl hydrocarbon receptor, interleukin-17, small-molecule inhibitors, randomised controlled trials, herb–drug interactions